Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Docetaxel in Metastatic or Inoperable Medullary Thyroid Cancer
2006-005301-63Phase 2Completed
- Sponsor
- University Hospital Vienna
- Start
- Dec 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in Medullary Thyroid Cancer (MTC), sponsored by University Hospital Vienna. Primary endpoints: Objective tumor response and Safety and tolerability. Started Dec 2006; status: completed.
02
Drugs
docetaxel
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on 2006-005301-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005301-63.